HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board
This article was originally published in The Tan Sheet
You may also be interested in...
Switch Paradigm Change Sees Long Road, Breeds Questions
Industry has opposed establishing an intermediate class of drugs between Rx and OTC, and FDA has held it does not have authority to require firms to allow products to be approved for behind-the-counter access or some other alternative distribution. But the creation of some form of third route to access appears likely.
Switch Paradigm Change Sees Long Road, Breeds Questions
Industry has opposed establishing an intermediate class of drugs between Rx and OTC, and FDA has held it does not have authority to require firms to allow products to be approved for behind-the-counter access or some other alternative distribution. But the creation of some form of third route to access appears likely.
Switch Paradigm Change Sees Long Road, Breeds Questions
Industry has opposed establishing an intermediate class of drugs between Rx and OTC, and FDA has held it does not have authority to require firms to allow products to be approved for behind-the-counter access or some other alternative distribution. But the creation of some form of third route to access appears likely.